Literature DB >> 23632359

Decompensated cirrhotics have slower intestinal transit times as compared with compensated cirrhotics and healthy controls.

Bani Chander Roland1, Guadalupe Garcia-Tsao, Maria M Ciarleglio, Yanhong Deng, Anish Sheth.   

Abstract

BACKGROUND: Altered small intestinal motility in cirrhotics may play a major role in the development of bacterial translocation (BT) by leading to small intestinal bacterial overgrowth. BT has been implicated in the development of several complications including spontaneous bacterial peritonitis, esophageal variceal hemorrhage, and hepatorenal syndrome. Prior studies using antroduodenal manometry to evaluate intestinal motility have shown discrepancies regarding the relationship between dysmotility and the severity of cirrhosis.
OBJECTIVES: (1) To characterize the frequency of small bowel motility disturbances in cirrhotic patients using a wireless motility capsule (SmartPill); (2) To assess the relationship of intestinal dysmotility with liver disease severity and cirrhosis complications; and (3) To compare intestinal transit times and motility indices among cirrhotics and healthy controls.
METHODS: We conducted a prospective study of 20 patients with cirrhosis (10 compensated, 10 decompensated) who were recruited from Yale New Haven Hospital and Hepatology clinics (February 2011 to July 2011). All patients underwent and completed SmartPill studies. Intestinal transit times were calculated, analyzed, and compared among compensated versus decompensated cirrhotics versus historical, healthy controls. Intestinal transit delays/motility indices were correlated with disease severity and complications.
RESULTS: Decompensated cirrhotics had significantly longer small bowel transit times (SBTT) as compared with compensated cirrhotics (6.17 vs. 3.56 h, P=0.036). There was a significant correlation (r=0.77, P=0.0003) between SBTT and cirrhosis severity as assessed by Child-Pugh score. There were no statistical differences noted between the groups for gastric or colonic transit times, although there was a trend toward prolonged transit throughout the gut in decompensated. Cirrhotics with spontaneous bacterial peritonitis and ascites also had significantly longer SBTT as compared with those without.
CONCLUSIONS: This study demonstrates that decompensated cirrhotics have slower intestinal transit times as compared with compensated cirrhotics and healthy controls. Additional prospective studies are needed to further characterize dysmotility in cirrhotics and its relationship to complications related to BT. This would aid in the identification of patients at risk for developing severe complications and who may benefit from prophylactic prokinetic and/or antimicrobial therapy.

Entities:  

Mesh:

Year:  2013        PMID: 23632359     DOI: 10.1097/MCG.0b013e31829006bb

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  19 in total

1.  Portal hypertensive enteropathy, occult bleeding, and capsule endoscopy: where do we go from here?

Authors:  Konstantinos J Dabos; Anastasios Koulaouzidis
Journal:  Dig Dis Sci       Date:  2014-05       Impact factor: 3.199

2.  Cirrhotic Patients Have Worse Bowel Preparation at Screening Colonoscopy than Chronic Liver Disease Patients without Cirrhosis.

Authors:  Anika K Anam; Kunal Karia; Arun B Jesudian; Brian P Bosworth
Journal:  J Clin Exp Hepatol       Date:  2016-08-31

Review 3.  Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis.

Authors:  Gaurav Ghosh; Arun B Jesudian
Journal:  J Clin Exp Hepatol       Date:  2018-08-27

Review 4.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

Review 5.  Gastrointestinal dysfunction in liver cirrhosis.

Authors:  Evangelos Kalaitzakis
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 6.  Novel prevention strategies for bacterial infections in cirrhosis.

Authors:  Kathleen Yan; Guadalupe Garcia-Tsao
Journal:  Expert Opin Pharmacother       Date:  2016-02-23       Impact factor: 3.889

Review 7.  Nutrition in Chronic Liver Disease.

Authors:  Yala Kirthi Reddy; Benedict Maliakkal; Uchenna Agbim
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 8.  Changes of Intestinal Functions in Liver Cirrhosis.

Authors:  Hiroshi Fukui; Reiner Wiest
Journal:  Inflamm Intest Dis       Date:  2016-03-08

9.  SmartPill® as an objective parameter for determination of severity and duration of postoperative ileus: study protocol of a prospective, two-arm, open-label trial (the PIDuSA study).

Authors:  Tim O Vilz; Dimitrios Pantelis; Philipp Lingohr; Rolf Fimmers; Anke Esmann; Thomas Randau; Jörg C Kalff; Martin Coenen; Sven Wehner
Journal:  BMJ Open       Date:  2016-07-08       Impact factor: 2.692

10.  Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology.

Authors:  Yanfei Chen; Feng Ji; Jing Guo; Ding Shi; Daiqiong Fang; Lanjuan Li
Journal:  Sci Rep       Date:  2016-09-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.